An observational study in Wilms Tumor, sponsored by South Egypt Cancer Institute. Recruiting at 1 site in Egypt. Open to participants aged Up to 18 Years. Per ClinicalTrials.gov, last updated 2024-03-01.
Sponsored by South Egypt Cancer Institute · Observational
The goal of this cross sectional observational study is to determine the percentage of Wilms tumors among pediatric cancers at Shefa Al-Orman Children Cancer Hospital from june 2020 to june 2024,to study the outcome of patients with Wilms tumor treated according to SIOP Umbrella protocol during the study period and to study the treatment related complications during therapy according to common terminology criteria of adverse events version 5.0 (CTCAE Version 5.0).
Research Design and Methods:
Study design: cross sectional study Study setting: Shefa Al-Orman Children Cancer hospital Study period: from June 2020 to June 2024
Study Objectives:
Data collection: Each patient is subjected to all the following according to the centre policy:
I. History and physical examination at presentation:
Clinical history and Physical examination including
II. Laboratory studies done for diagnosis of renal tumors at presentation:
III. Imaging Studies:
Abdominal CT scan or MRI with special attention to
* Presence and function of the opposite kidney
*Evidence of bilateral lesions
*Evidence of involvement of renal vein or inferior vena cava with tumor
*Lymph node involvement
*Liver metastasis
Echocardiography: To
IV. Pathology:
Ultrasound or CT guided True cut needle biopsy is indicated in the following conditions:
A- Unusual clinical presentations:
B- Unusual findings by imaging:
C- Contraindications for the use of Needle Biopsy:
V. Reporting of treament related complications include:
Chemotherapy toxicity will be determined according to WHO Common Terminology Criteria for Adverse Events (CTCAE Version 5.0, 2017) (2).
VI. Treatment: Patients are treated according to SIOP Umbrella protocol (1)
200 studies on the registry are indexed under Wilms Tumor; 25 are open to participants now.
This study's planned enrollment of 50 is below the median of 162 across 36 observational studies indexed under Wilms Tumor.
Browse Wilms Tumor studies →South Egypt Cancer Institute is the lead sponsor of 35 studies on the registry; 7 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Children and young adolescene younger than 18 years of age admitted and treated at Shefa Al-orman Children Cancer Hospital during the study period
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Overall-survival (OS)
will be calculated from date of diagnosis to last date of follow up or date of death for any cause
Time frame: from date of diagnosis to last date of follow up or date of death for any cause
Event-free survival (EFS)
will be measured from the date of Wilms tumor diagnosis to the first treatment failure or date of last follow-up. Treatment failure included abandonment of treatment, death, and progressive or relapsed disease.
Time frame: the date of Wilms tumor diagnosis to the first treatment failure or date of last follow-up. Treatment failure included abandonment of treatment, death, and progressive or relapsed disease.
Plan to share: No
Started Jun 2020 (actual). Primary completion is estimated for Jun 2024, 48 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
South Egypt Cancer Institute